Articles related to Pathology

This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo.

Day two of ASCO 2020 featured late-breaking data from a phase 3 trial evaluating early local therapy in metastatic breast cancer, as well as results of the phase 3 ENDURANCE trial, the ALPHA CAR T-cell trial, and the C-144-01 trial assessing TIL therapy.

Gastrointestinal and breast cancer sessions were featured on the first day of the virtual conference, highlighting practice-changing results from a multitude of studies, including the HER2CLIMB, MINDACT, and PHERGAIN trials.

According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.

On May 31, 2020, at the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Sessions, late-breaking data dropped for three potentially practice-changing studies: JAVELIN Bladder 100, KEYNOTE-177, and ADAURA.

Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.